ASRS 2023: Fernando Arevalo on retinal detachments associated to retinoschisis

News
Video

Fernando Arevalo, MD, PhD, FACS, FASRS, shared information on his presentation on the treatment of progressively symptomatic retinal detachments associated to retinoschisis cases at the 2023 ASRS annual meeting.

Fernando Arevalo, MD, PhD, FACS, FASRS, shared information on his ASRS 2023 presentation, which focussed on the treatment of progressively symptomatic retinal detachments associated to retinoschisis cases. Arevalo is a member of the Modern Retina board.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Fernando Arevalo, MD, PhD, FACS, FASRS:

Hello, my name is Fernando Arevalo, and I'm a professor of ophthalmology at Johns Hopkins University and Wilmer Eye Institute in Baltimore, Maryland. I'm here in Seattle at the American Society of Retinal Specialists, and 1 of the things that I am presenting is the treatment of progressively symptomatic retinal detachments associated to retinoschisis cases.

I presented on a patient that had, or was treated with, phaco-vitrectomy and retinectomy to repair one of those complex detachments. We performed a complete vitrectomy with peripheral vitrectomy as well, the use of perfluorocarbon to flood in the retina, and that was to some traction in the periphery with the phaco to allow us to do more peripheral shaving. And even with that there was still some traction and elevation in the periphery.


In addition, the patient had already a 41 band [in] place, and with this traction still in the periphery, I decided to perform a retinectomy. Basically the roofing of the inner retina to allow the area of the retina peripherally to flatten, and that allowed the retina to reattach when the laser was applied, perfluorocarbon was injected, and then an [inaudible] change and then silicone oil because it was a monocular patient, but gas can also be used.

This technique comes from a study that we published recently on 18 cases with progressively symptomatic retinal detachment associated retinas cases where we usually, most of the cases combination of a buckle and vitrectomy. And we found that, in a follow up of about 4 years, there were a third of patients that had a failure with 1 surgery. Although their final success rate was 100%, I think that the fact that the 1 surgery success rate was only 66% emphasises how difficult it is to repair, these retinal detachments. And more research is needed to evaluate what are the best surgical techniques to repair these kinds of retinal detachments.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.